Role of stem cell transplant and maintenance therapy in plasma cell disorders

Philip L. McCarthy, Sarah A Holstein

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Autologous stem cell transplant (ASCT) has been an important component of therapy for myeloma patients eligible for high-dose chemotherapy. Recent studies comparing early transplant to low-dose chemotherapy support the continued use of ASCT as consolidation following induction therapy, even in the era of immunomodulatory drugs, proteasome inhibitors, and other novel agents. Despite the marked improvements in outcomes with this approach, most patients will eventually experience disease progression. Thus, inclusion of post-ASCT consolidation/maintenance strategies is used to improve long-term disease control. Multiple randomized studies support the use of lenalidomide maintenance therapy following ASCT. The next generation of clinical trials will incorporate novel agents such as monoclonal antibodies, proteasome inhibitors, and other novel pathway modulatory agents into post-ASCT treatment strategies with the goal of achieving even deeper responses and longer durations of disease control.

Original languageEnglish (US)
Pages (from-to)504-511
Number of pages8
JournalHematology
Volume2016
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Transplants
Plasma Cells
Stem cells
Stem Cells
Plasmas
Disease control
Proteasome Inhibitors
Chemotherapy
Consolidation
Therapeutics
Drug Therapy
Disease Progression
Monoclonal Antibodies
Maintenance
Clinical Trials
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Role of stem cell transplant and maintenance therapy in plasma cell disorders. / McCarthy, Philip L.; Holstein, Sarah A.

In: Hematology, Vol. 2016, No. 1, 01.01.2016, p. 504-511.

Research output: Contribution to journalArticle

@article{bed72b53841746188e5ba80cb8ac6d3d,
title = "Role of stem cell transplant and maintenance therapy in plasma cell disorders",
abstract = "Autologous stem cell transplant (ASCT) has been an important component of therapy for myeloma patients eligible for high-dose chemotherapy. Recent studies comparing early transplant to low-dose chemotherapy support the continued use of ASCT as consolidation following induction therapy, even in the era of immunomodulatory drugs, proteasome inhibitors, and other novel agents. Despite the marked improvements in outcomes with this approach, most patients will eventually experience disease progression. Thus, inclusion of post-ASCT consolidation/maintenance strategies is used to improve long-term disease control. Multiple randomized studies support the use of lenalidomide maintenance therapy following ASCT. The next generation of clinical trials will incorporate novel agents such as monoclonal antibodies, proteasome inhibitors, and other novel pathway modulatory agents into post-ASCT treatment strategies with the goal of achieving even deeper responses and longer durations of disease control.",
author = "McCarthy, {Philip L.} and Holstein, {Sarah A}",
year = "2016",
month = "1",
day = "1",
doi = "10.1182/asheducation-2016.1.504",
language = "English (US)",
volume = "2016",
pages = "504--511",
journal = "ImmunoMethods",
issn = "1046-2023",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Role of stem cell transplant and maintenance therapy in plasma cell disorders

AU - McCarthy, Philip L.

AU - Holstein, Sarah A

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Autologous stem cell transplant (ASCT) has been an important component of therapy for myeloma patients eligible for high-dose chemotherapy. Recent studies comparing early transplant to low-dose chemotherapy support the continued use of ASCT as consolidation following induction therapy, even in the era of immunomodulatory drugs, proteasome inhibitors, and other novel agents. Despite the marked improvements in outcomes with this approach, most patients will eventually experience disease progression. Thus, inclusion of post-ASCT consolidation/maintenance strategies is used to improve long-term disease control. Multiple randomized studies support the use of lenalidomide maintenance therapy following ASCT. The next generation of clinical trials will incorporate novel agents such as monoclonal antibodies, proteasome inhibitors, and other novel pathway modulatory agents into post-ASCT treatment strategies with the goal of achieving even deeper responses and longer durations of disease control.

AB - Autologous stem cell transplant (ASCT) has been an important component of therapy for myeloma patients eligible for high-dose chemotherapy. Recent studies comparing early transplant to low-dose chemotherapy support the continued use of ASCT as consolidation following induction therapy, even in the era of immunomodulatory drugs, proteasome inhibitors, and other novel agents. Despite the marked improvements in outcomes with this approach, most patients will eventually experience disease progression. Thus, inclusion of post-ASCT consolidation/maintenance strategies is used to improve long-term disease control. Multiple randomized studies support the use of lenalidomide maintenance therapy following ASCT. The next generation of clinical trials will incorporate novel agents such as monoclonal antibodies, proteasome inhibitors, and other novel pathway modulatory agents into post-ASCT treatment strategies with the goal of achieving even deeper responses and longer durations of disease control.

UR - http://www.scopus.com/inward/record.url?scp=85020291236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020291236&partnerID=8YFLogxK

U2 - 10.1182/asheducation-2016.1.504

DO - 10.1182/asheducation-2016.1.504

M3 - Article

C2 - 27913522

AN - SCOPUS:85020291236

VL - 2016

SP - 504

EP - 511

JO - ImmunoMethods

JF - ImmunoMethods

SN - 1046-2023

IS - 1

ER -